Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
03/22/2017 03/23/2017 03/24/2017 03/27/2017 03/28/2017 Date
250.2(c) 252.6(c) 252.9(c) 252.9(c) 253 Last
1 497 663 1 429 215 1 312 545 1 055 916 514 792 Volume
+0.04% +0.96% +0.12% 0.00% +0.04% Change
More quotes
Financials ( CHF)
Sales 2017 53 154 M
EBIT 2017 18 423 M
Net income 2017 11 484 M
Debt 2017 8 962 M
Yield 2017 3,39%
Sales 2018 56 087 M
EBIT 2018 19 762 M
Net income 2018 12 985 M
Debt 2018 2 941 M
Yield 2018 3,61%
P/E ratio 2017 18,74
P/E ratio 2018 17,10
EV / Sales2017 4,25x
EV / Sales2018 3,92x
Capitalization 217 078 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
03/29Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
07:09a ROCHE : announces launch of cobas HPV on the cobas 6800/8800 Systems for cervica..
06:21a ROCHE : Addressing Threat Of Zika Virus To US Blood Supply
03/27 ROCHE : Health and Human Services Department (HHS); Food and Drug Administration..
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/27 ROCHE : Dying patients want easier access to experimental drugs
03/25 ROCHE : Rituxan For Pemphigus Vulgaris Gets Breakthrough Therapy Designation
03/25 Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 ROCHE : FDA grants breakthrough therapy designation for MabThera/Rituxan (rituxi..
03/24 ROCHE : FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in ..
03/24 ROCHE : Rep. Speier to Host 'When I Grow Up...' for Elementary and Middle School..
More news
Sector news : Pharmaceuticals - NEC
08:48aDJDuPont, Dow Get EU Approval for Merger -- WSJ
03/27DJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
03/27DJEU Clears Dow-DuPont Deal With Conditions -- 2nd Update
03/27DJEU Clears Dow-DuPont Deal With Conditions -- Update
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ROCHE HOLDING LTD. 
2016An opportunity over the medium term?
2016A medium term support level to take advantage of
More Strategies
Latest Tweets
04:45a“We’re expecting significant damage.” Deputy Commissioner Mark Roche as sta..
23
03:08aQFES Deputy Commissioner Mark Roche: we don't need any sightseers in the afte..
8
02:39a Deputy Commissioner Mark Roche says will bring 'significant winds and peopl..
12
02:37a"This really is early stages. We believe there will be significant structural..
1
01:00a“In a days’ time we can talk about the destruction of the cyclone & not a..
8
More tweets
Qtime:127
News from SeekingAlpha
03/27 My Favorite Biotech Takeover Play
03/27 Alzheimer's Cure Is Science's Holy Grail - Will Biogen Find It?
03/27 PROTALIX BIOTHERAPEUTICS : High Expectations For Upcoming Phase 2 Cystic Fibrosi..
03/24 Roche's Rituxan a Breakthrough Therapy for rare autoimmune skin disorder
03/24 FDA grants breakthrough therapy designation for Rituxan in pemphigus vulgaris
Advertisement
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 281  CHF
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.8.73%220 248
JOHNSON & JOHNSON8.91%341 030
PFIZER INC.5.23%203 546
NOVARTIS AG-0.47%195 735
MERCK & CO., INC.7.34%173 493
SANOFI7.76%117 163
More Results